AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Italy Fines Apple €98.6 Million Over App Store Dominance 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
VELDHOVEN, the Netherlands - ASML Holding N.V. (ASML) reports the following transactions, conducted under ASML's current share buyback program.
| Date | Total repurchased shares | Weighted average price | Total repurchased value |
| 17-Jul-17 | - | - | |
| 18-Jul-17 | - | - | |
| 19-Jul-17 | - | - | |
| 20-Jul-17 | 24,000 | 131.33 | 3,151,960.61 |
| 21-Jul-17 | 38,000 | 131.39 | 4,992,726.75 |
ASML's current share buyback program was announced on 20 January 2016, and details are available on our website at https://www.asml.com/investors/share-buyback/en/s25436
This regular update of the transactions conducted under the buyback program is to be made public under the Market Abuse Regulation (Nr. 596/2014).
| Media Relations Contacts | Investor Relations Contacts |
| Monique Mols, phone +31 6 528 444 18 | Craig DeYoung, phone +1 480 696 2762 |
| Niclas Mika, phone +31 6 201 528 63 | Marcel Kemp, phone +31 40 268 6494 |
